Daiichi posts another Ranbaxy-related loss; Lilly wins FDA nod for combo diabetes pill;

@FiercePharma: Two chairmen replaced as J&J takes another crack at overhauling McNeil, WSJ reports. Article | Follow @FiercePharma

> Japan's Daiichi Sankyo saw its latest earnings weighed down once again by majority-owned subsidiary Ranbaxy Laboratories, the Indian drugmaker that recently signed a consent decree with FDA. More

> Eli Lilly ($LLY) won the FDA nod for its diabetes treatment Jentadueto, which combines the commonly used treatment metformin with its newer drug Tradjenta, sold in partnership with Germany's Boehringer Ingelheim. News

> Biogen Idec ($BIIB) said spending on drug trials and launches will cause lower-than-expected earnings for 2012, as its multiple sclerosis drug Tysabri posted sales growth of 14%, lower than Wall Street estimates. Report

> The standard diabetes therapy metformin was associated with fewer cases of pancreatic cancer, a study showed, while other diabetes drugs were found to be associated with a higher risk of the disease. Article

> Generics maker Lannett won FDA approval for its version of the Watson Pharmaceuticals ($WPI) blood-pressure drug Microzide. Story

> The drug distributor McKesson agreed to pay $918 million for marketing and franchising businesses associated with 1,000 independent Canadian pharmacies. Report

> Regulators in Saudi Arabia have proposed a code of ethics for companies manufacturing and marketing pharmaceutical products. More

Biotech News

@FierceBiotech: Lilly's losses put pressure on key Alzheimer's program. How will Lechleiter's R&D strategy fare? Article | Follow @FierceBiotech

@JohnCFierce: Ketamine ("Special K") for depression? Being studied in IV form, also new pill. Story | Follow @JohnCFierce

@RyanMFierce: Lilly ($LLY) gained an FDA nod for a linagliptin-metformin combo pill for diabetes partnered with Boehringer. News | Follow @RyanMFierce

@MarkHFierce: A 2,200 year old mummy had prostate cancer. Researchers say the finding proves cancer is caused by genetics. More | Follow @MarkHFierce

> BREAKING: Vertex nabs expedited FDA OK on breakthrough CF drug. News

> Researchers study 'Special K' drug as potential tonic for depression. Story

> Biogen boosts R&D budget after research cutbacks. More

> Pfizer targets approval for new menopause drug. Article

> Analysts give Actelion's key lung drug 63% odds of success. Story

> BioSante axes 25% of workforce after big miss in female libido gel trials. News

Research News

> New target could be key to beating back methamphetamine addiction. More

> Meet cancer's latest enemy: grape seed extract. Article

> Team finds 2 mutations that cause pediatric brain cancer. More

> Mutated melanoma receptor heightens diabetes risk. Story

> Nearly $11M to fund new Joslin Diabetes Center research facility. Item

Pharma Manufacturing News

> Teva's Cephalon recalls leukemia drug over fragments in vial. News

> Pfizer workers at manufacturing hub sue over whiplashed retirement plans. Article

> Company whistleblower program part of Ranbaxy consent decree. News

> Gutted J&J consumer healthcare plant another year from reopening. Story

> Medicines Company, APP settlement includes manufacturing agreement. Item

And Finally... Skin patches may be a better delivery method for allergy-fighting immunotherapy, a study found. Report